ERS Genomics

Gene editing gene therapy CRISPR

CRO

Crown Bioscience inks deal with ERS for gene editing technology

Crown Bioscience inked a licensing deal with ERS Genomics to use its CRISPR/Cas9 patent portfolio for gene editing in drug development.

Joseph Keenan Dec 12, 2022 3:05pm

DNA

U.S. CRISPR rights battle heats up as UC team launches appeal

Jul 26, 2017 9:53am